Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial

Diederichsen ACP, Lindholt JS, Möller S, et al. · Circulation

The largest MK-7 calcification trial is null on its primary endpoint: aortic valve calcification rose 275 units on treatment and 292 on placebo, a difference of 17 units (95% CI -86 to 53, P=0.64), with no effect on valve area (P=0.78), jet velocity (P=0.21), or aortic and coronary calcification — despite inactive matrix Gla protein falling sharply (-212 vs +45 pmol/L, P<0.001). Carboxylation improved and the calcium did not stop.

Population

Community-dwelling men, mean age 71, with an aortic valve calcification score above 300 arbitrary units, 24 months

Intervention

MK-7 720 ug plus vitamin D 25 ug daily

Comparator

Matching placebo

Limitations

Men aged 65-74 with established, advanced valve calcification, where any brake may come too late; MK-7 given with vitamin D, so the two cannot be separated; 24 months. Three valve replacements occurred in the whole trial, so it says nothing either way about clinical events. Registered as NCT03243890.